Effects of seven drugs of abuse on action potential repolarisation in sheep cardiac Purkinje fibres

European Journal of Pharmacology

Volumn 511, Issue 2-3, 2005, Pages 99-107

  Sheridan, Robert D ^a   Turner, Simon R ^a   Cooper, Graham J ^a   Tattersall, John E H ^a  

^a DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

Author keywords

'Ecstasy'; (+) methamphetamine; Cocaethylene; Cocaine; Morphine; Phencyclidine; Sheep Purkinje fibre; 9 tetrahydrocannabinol

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; COCAINE; DIAMORPHINE; DRONABINOL; HOMOCOCAINE; METHAMPHETAMINE; MORPHINE; PHENCYCLIDINE;

ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; DRUG ABUSE; DRUG EFFECT; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; MALE; MUSCLE ACTION POTENTIAL; NONHUMAN; PRIORITY JOURNAL; PURKINJE FIBER; QT PROLONGATION; SHEEP; STATISTICAL SIGNIFICANCE; TORSADE DES POINTES;

EID: 15744372491     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2005.02.015     Document Type: Article

References (53)

1. D.N. Bailey Phencyclidine abuse. Clinical findings and concentrations in biological fluids after nonfatal intoxication Am. J. Clin. Pathol. 72 1979 795 799
2. D.N. Bailey Comprehensive review of cocaethylene and cocaine concentrations in patients Am. J. Clin. Pathol. 106 1996 701 704
3. D.N. Bailey Effect of drugs and cocaine metabolites on cocaine and cocaethylene binding to human serum in vitro Ther. Drug Monit. 19 1997 427 430
4. C.H. Barton, M.L. Sterling, and N.D. Vaziri Phencyclidine intoxication: clinical experience in 27 cases confirmed by urine assay Ann. Emerg. Med. 10 1981 243 246
5. L. Belardinelli, C. Antzelevitch, and M.A. Vos Assessing predictors of drug-induced torsade de pointes Trends Pharmacol. Sci. 24 2003 619 625
6. M. Boutjdir, M. Assadi, and N. el-Sherif Electrophysiologic effects of cocaine on subendocardial Purkinje fibers surviving 1 day of myocardial infarction J. Cardiovasc. Electrophysiol. 6 1995 729 736
7. W.H. Bunn, and A.J. Giannini Cardiovascular complications of cocaine abuse Am. Fam. Phys. 46 1992 769 773
8. C.W. Clarkson, C. Chang, A. Stolfi, W.J. George, S. Yamasaki, and A.S. Pickoff Electrophysiological effects of high cocaine concentrations on intact canine heart. Evidence for modulation by both heart rate and autonomic nervous system Circulation 87 1993 1046 1047
9. C.W. Clarkson, Y.-Q. Xu, C. Chang, and C.H. Follmer Analysis of the ionic basis for cocaine's biphasic effect on action potential duration in guinea-pig ventricular myocytes J. Mol. Cell. Cardiol. 28 1996 667 678
10. J. Condon, and N. Smith Prevalence of drug use: key findings from the 2002/2003 British Crime Survey Home office research findings No. 229 2003 Home Office London Document online at http://www.homeoffice.gov.uk/rds/pdfs2/r229.pdf
11. E.J. Cone, and M.A. Huestis Relating blood concentrations of tetrahydrocannabinol and metabolites to pharmacologic effects and time of marijuana usage Ther. Drug Monit. 15 1993 527 532
12. G.A. D'Amico, G.P. Kline, and S. Maayani Effects of phencyclidine on the cardiac action potential: pH dependence and structure-activity relationships Eur. J. Pharmacol. 88 1983 283 290
13. S. Darke, S. Sunjic, D. Zador, and T. Prolov A comparison of blood toxicology of heroin-related deaths and current heroin users in Sydney, Australia Drug Alcohol Depend. 47 1997 45 53
14. B. Darpö Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes Eur. Heart J. 3 Suppl. K 2001 K70 K80
15. DEA, 2003. Drug Enforcement Administration Drug Intelligence Brief. PCP: The Threat Remains (Document online at http://www.usdoj.gov/dea/pubs/intel/ 03013/index.html).
16. R. De La Torre, M. Farré, J. Ortuno, M. Mas, R. Brenneisen, P.N. Roset, J. Segura, and J. Cami Non-linear pharmacokinetics of MDMA ('Ecstasy') in humans Br. J. Clin. Pharmacol. 49 2000 104 109
17. F. De Ponti, E. Poluzzi, and N. Montanaro Organising evidence on QT prolongation and occurrence of torsades de pointes with non-antiarrhythmic drugs: a call for consensus Eur. J. Clin. Pharmacol. 57 2001 185 209
18. G.P. Dowling, E.T. McDonough III, and R.O. Bost 'Eve' and 'Ecstasy': a report of five deaths associated with the use of MDEA and MDMA JAMA 257 1987 1615 1617
19. W.M. Drake, and P.A. Broadhurst QT-interval prolongation with Ecstasy S. Afr. Med. J. 86 1996 180 181
20. D.J. Edwards, and S.K. Bowles Protein binding of cocaine in human serum Pharm. Res. 5 1988 440 442
21. R.R. Fenichel, M. Malik, C. Antzelevitch, M. Sanguinetti, D.M. Roden, S.G. Priori, J.N. Ruskin, R.J. Lipicky, and L.R. Cantilena Drug-induced torsades de pointes and implications for drug development J. Cardiovasc. Electrophysiol. 15 2004 475 495
22. S. Ferreira, W.J. Crumb Jr., C.G. Carlton, and C.W. Clarkson Effects of cocaine and its major metabolites on the HERG-encoded potassium channel J. Pharmacol. Exp. Ther. 299 2001 220 226
23. W.H. Frishman, A. Del Vecchio, S. Sanal, and A. Ismail Cardiovascular manifestations of substance abuse: Part 2. Alcohol, amphetamines, heroin, cannabis, and caffeine Heart Dis. 5 2003 253 271
24. E.R. Garrett, K. Seyda, and P. Marroum High performance liquid chromatographic assays of the illicit designer drug "Ecstasy," a modified amphetamine, with applications to stability, partitioning and plasma protein binding Acta Pharm. Nord. 3 1991 9 14
25. H.G. Giles, W.A. Corrigall, V. Khouw, and E.M. Sellers Plasma protein binding of phencyclidine Clin. Pharmacol. Ther. 31 1982 77 82
26. L.S. Goodman, and A. Gilman J.G. Hardman L.E. Limbird The pharmacological basis of therapeutics Ninth edition 1996 McGraw-Hill New York 1762
27. R.W. Hadley, and J.R. Hume Actions of phencyclidine on the action potential and membrane currents of single guinea pig myocytes J. Pharmacol. Exp. Ther. 237 1986 131 136
28. D.J. Harvey Absorption, distribution, and biotransformation of the cannabinoids G.G. Nahas K.M. Sutin D. Harvey S. Agurell Marihuana and medicine 1999 Humana Press Totowa, NJ 105 116
29. L.M. Hondeghem, and D.J. Snyders Class III antiarrhythmic agents have a lot of potential but a long way to go: reduced effectiveness and dangers of reverse use-dependence Circulation 81 1990 686 690
30. R. Hong, E. Matsuyama, and K. Nur Cardiomyopathy associated with the smoking of crystal methamphetamine JAMA 265 1991 1152 1154
31. S. Kimura, A.L. Bassett, H. Xi, and R.J. Myerburg Early afterdepolarizations and triggered activity induced by cocaine. A possible mechanism of cocaine arrhythmogenesis Circulation 85 1992 2227 2235
32. S.E. Lerner, and R.S. Burns Legal issues associated with PCP abuse-the role of the forensic expert NIDA Res. Monogr. 64 1986 229 236
33. L.A. Marsch, W.K. Bickel, G.J. Badger, J.P. Rathmell, M.D.B. Swedberg, B. Jonzon, and C. Norsten-Höög Effects of infusion rate of intravenously administered morphine on physiological, psychomotor, and self-reported measures in humans J. Pharmacol. Exp. Ther. 299 2001 1056 1065
34. R.L. Martin, J.S. McDermott, H.J. Salmen, J. Palmatier, B.F. Cox, and G.A. Gintant The utility of hERG and repolarisation assays in evaluating delayed cardiac repolarisation: influence of multi-channel block J. Cardiovasc. Pharmacol. 43 2004 369 379
35. M. Mas, M. Farré, R. De La Torre, P.N. Roset, J. Ortuno, J. Segura, and J. Cami Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans J. Pharmacol. Exp. Ther. 290 1999 136 145
36. J.A. Mercy, C.W. Heath Jr., and M.L. Rosenberg Mortality associated with the use of upper-body control holds by police Violence Vict. 5 1990 215 222
37. U.A. Meyer Pharmacogenetics and adverse drug reactions Lancet 356 2000 1667 1671
38. M.A. Mittleman, D. Mintzer, M. Maclure, G.H. Tofler, J.B. Sherwood, and J.E. Muller Triggering of myocardial infarction by cocaine Circulation 99 1999 2737 2741
39. M.E. O'Leary Inhibition of human ether-a-go-go potassium channels by cocaine Mol. Pharmacol. 59 2001 269 277
40. + channel. A model for bad behaviour J. Med. Chem. 46 2003 2017 2022
41. R. Perera, A. Kraebber, and M.J. Schwartz Prolonged QT interval and cocaine use J. Electrocardiol. 30 1997 337 339
42. W.S. Redfern, L. Carlsson, A.S. Davis, W.G. Lynch, I. Mackenzie, S. Palethorpe, P.K. Siegl, I. Strang, A.T. Sullivan, R. Wallis, A.J. Camm, and T.G. Hammond Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development Cardiovasc. Res. 58 2003 32 45
43. K.M. Rentsch, G.A. Kullak-Ublick, C. Reichel, P.J. Meier, and K. Fattinger Arterial and venous pharmacokinetics of intravenous heroin in subjects who are addicted to narcotics Clin. Pharmacol. Ther. 70 2001 237 246
44. D.M. Roden Mechanisms and management of proarrhythmia Am. J. Cardiol. 82 1998 49I 57I
45. N. Samyn, G. De Boeck, M. Wood, C.T. Lamers, D. De Waard, K.A. Brookhuis, A.G. Verstraete, and W.J. Riedel Plasma, oral fluid and sweat wipe ecstasy concentrations in controlled and real life conditions Forensic Sci. Int. 128 2002 90 97
46. R.J. Schepers, J.M. Oyler, R.E. Joseph Jr., E.J. Cone, E.T. Moolchan, and M.A. Huestis Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers Clin. Chem. 49 2003 121 132
47. N. Singh, H.K. Singh, P.P. Singh, and I.A. Khan Cocaine-induced torsades de pointes in idiopathic long Q-T syndrome Am. J. Ther. 8 2001 299 302
48. R.M. Smith Ethyl esters of arylhydroxy- and arylhydroxymethoxy-cocaines in the urine of simultaneous cocaine and ethanol users J. Anal. Toxicol. 8 1984 38 42
49. K. Temma, T. Akera, and Y.C. Ng Cardiac actions of phencyclidine in isolated guinea pig and rat heart: possible involvement of slow channels J. Cardiovasc. Pharmacol. 7 1985 297 306
50. S. Viskin Long QT syndromes and torsade de pointes Lancet 354 1999 1625 1633
51. R.H. Williams, J.A. Maggiore, S.M. Shah, T.B. Erickson, and A. Negrusz Cocaine and its major metabolites in plasma and urine samples from patients in an urban emergency medicine setting J. Anal. Toxicol. 24 2000 478 481
52. L.D. Wilson, R.J. Henning, C. Suttheimer, E. Lavins, E. Balraj, and S. Earl Cocaethylene causes dose-dependent reductions in cardiac function in anesthetized dogs J. Cardiovasc. Pharmacol. 26 1995 965 973
53. S. Zhang, S. Rajamani, Y. Chen, Q. Gong, Y. Rong, Z. Zhou, A. Ruoho, and C.T. January Cocaine blocks HERG, but not KvLQT1+minK, potassium channels Mol. Pharmacol. 59 2001 1069 1076